Characteristics, specifications and related information of mitapivat-Pyrukynd

Mitapivat (mitapivat) -Pyrukynd is an oral medication designed to treat hemolytic anemia caused by pyruvate kinase (PK) deficiency. Pyruvate kinase deficiency is a rare genetic disease in which patients lack this key enzyme, resulting in abnormal function of red blood cells and resulting in anemia. The therapeutic goal of Metapival is to restore normal red blood cell production and function, reduce anemia symptoms, and improve the patient's overall health by activating pyruvate kinase activity.

Pyrukynd is available in three strengths, namely 5 mg, 20 mg and 50 mg oral tablets. Each tablet contains a corresponding dose of mitapival free base, with 5 mg, 20 mg and 50 mg corresponding to 5.85 mg, 23.4 mg and 58.5 mg of sulfate hydrate respectively. The drug is administered orally and acts directly on pyruvate kinase to improve red blood cell metabolism and function. Since the clinical manifestations and individual differences of PK deficiency are large, the dosage design of Metapival provides flexible space for selection and can be adjusted according to the different needs of patients.

Metapival was developed to provide a novel treatment option for patients with pyruvate kinase deficiency. Prior to this, the treatment options for PK deficiency were mainly symptomatic and lacked specific drugs. The emergence of Metapival fills this therapeutic gap. It activates pyruvate kinase, improves the glycolysis process, and ensures that red blood cells can obtain sufficient energy, thereby reducing hemolysis and alleviating anemia symptoms.

Metapival has shown significant efficacy in clinical trials. Studies have shown that Metapival can significantly increase patients' hemoglobin levels, reduce hemolysis, relieve anemia symptoms, and improve quality of life. Metapival provides a safe and effective treatment option for patients with pyruvate kinase deficiency.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd